Company Continues its Expansion into the Healthcare Professional Market through One-on-One Education, Exclusive Product Offerings and Enhanced Practitioner Support.
LAS VEGAS, April 18, 2018 -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company," "CV Sciences," "our" or "we"), preeminent manufacturer and distributor of the industry-dominating brand of hemp extract products, PlusCBD Oil™, announced today that it will be exhibiting at the 15th Annual Nutrition and Health Conference, held on April 29th to May 2nd, 2018 at the Westin Boston Waterfront in Boston, MA as a Silver Level Sponsor.
The Nutrition and Health Conference, produced by the Arizona Center for Integrative Medicine, is a continuing education conference that assembles internationally recognized researchers, clinicians, educators, and chefs whose work focuses on the interface between nutrition and healthful living. The conference will feature presentations and a lively panel discussion with renowned health expert Dr. Andrew Weil and nationally renowned nutrition experts discussing optimum diet and social and political issues related to food and nutrition.
Exhibiting brands are chosen based on philosophical fit of the organization’s values and mission, as well as representing quality products that serve the health and wellness of their attendees and patients. “We are thrilled to be the first hemp CBD company to sponsor and exhibit at the Nutrition and Health Conference,” stated Stuart Tomc, VP of Human Nutrition at CV Sciences. “Conference leadership has set a strict standard to ensure high-quality dietary supplements and foods are represented to their attendees, and we look forward to educating forward-thinking practitioners on the value hemp CBD products like PlusCBD Oil™ may offer their clients and patients.”
VISIT THE CV SCIENCES TABLE: CV Sciences invites attendees to visit the CV Sciences table to learn more about their botanical-based CBD product line, PlusCBD Oil™. The Company will additionally feature its brand of practitioner-exclusive products available only to healthcare providers nationwide. Also, CV Sciences will be offering exclusive trade show discounts and show specials to practitioners attending the show.
About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in San Diego, California and Las Vegas, Nevada. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.
CONTACT:
Robert Haag, Managing Director
IRTH Communications
[email protected]
866-976-4784


Toyota Global Sales Fall as China Demand Slumps
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China
Meta, U.S. States Discuss Settlement in Teen Addiction Trial
Google Changes EU Spam Policy Amid Antitrust Scrutiny
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook
Street Poller Media and The Boom of the Street Interview Ad Industry
Trump Administration Plans New Drug Pricing Deals With Biotech Firms
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation
OpenAI Data Center Chief Chris Malone Exits Ahead of Planned 2027 Listing
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim
Itochu Offers $1.56 Billion to Privatize Dentsu Soken
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan
Jefferies Names AMEC Top China Semiconductor Equipment Pick
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake
Nvidia Pauses AI Cloud Financing Deals Amid Antitrust Concerns 



